JPRN-jRCT2031220211招募中1 期
A Phase I Study to Explore the Pharmacokinetics of Clofazimine in Combination with Three Antimicrobial Drugs in Japanese Patients with Pulmonary MABC Disease - MYCAT
Ho Namkoong0 个研究点目标入组 10 人开始时间: 2022年7月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •(Selection criteria to be confirmed at the time of obtaining consent)
- •When obtaining consent, the investigator shall confirm the following 1) to 7) from the medical record, and confirm that the subject is able or willing to comply with 8) and 9).
- •1) The subject has obtained written consent from the patient himself/herself to participate in this clinical trial.
- •2) Japanese* patients with pulmonary MABC who meet the diagnostic criteria of the 2020 ATS/ERS/ESCMID/IDSA guideline.
- •*Japanese means the person/parents are Japanese nationals and the maternal and paternal grandparents are Japanese nationals.
- •3) Patients whose age at the time of obtaining consent is between 20 and 85 years old
- •4) Patients with clinical symptoms (sputum, cough, hemoptysis, chest pain, shortness of breath, fatigue, fever, night sweats, anorexia, weight loss, etc.) due to pulmonary MABC disease at the time of obtaining consent
- •5) Patients with imaging findings (bronchiectasis, granular shadows, small nodular shadows, cavernous lesions, infiltrative shadows, etc. on chest CT) due to pulmonary MABCS. Imaging findings should be confirmed by imaging taken within 6 months prior to the start of screening.
- •6) Must be able to take the study medication for the duration of the clinical trial.
- •7) No history of antimicrobial agents with antimicrobial activity against pulmonary MABC disease within 4 weeks prior to the start of screening
- •8) Patients who can be hospitalized for 16 days from the day before the start of treatment
- •9) Female patients of childbearing potential who agree to use contraception during the study period and for at least 4 months after the last dose of clofazimine
- •(Selection criteria to be confirmed during the screening period)
- •10) Patients with at least one positive sputum culture or bronchoscopic specimen culture within 6 months prior to screening and with a positive culture specimen at screening. If the pre-screening positive is confirmed by sputum culture, the patient must have been positive at least twice, and one of those times must have been confirmed within 6 months prior to screening.
排除标准
- •1) Patients with a history of oral administration of clofazimine
- •2) Patients with a history of hypersensitivity to Lampren, clarithromycin, amikacin, or any component of imipenem hydrate or cilastatin sodium
- •3) Patients receiving drugs contraindicated in the most recent clarithromycin package insert including pimozide, ergotamine tartrate/caffeine anhydrous, isopropylantipirine, suvorexant, lomitapide mesylate, tadalafil(adcirca), ticagrelor, ibrutinib, ibabradine hydrochloride, venetoclax (in the dose escalation phase of relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma) during the dose-escalation phase), lurasidone hydrochloride, and anamorelin hydrochloride (contraindication to clarithromycin), etc.
- •4) Patients with hepatic or renal impairment who are receiving colchicine (contraindication to clarithromycin)
- •5) Patients with a history of hypersensitivity to aminoglycoside antibiotics or bacitracin (contraindication to amikacin)
- •6) Patients with hearing loss or other hearing impairment due to aminoglycoside antibiotics in the patient or a blood relative (contraindication to Amikacin in principle)
- •7) Patients receiving sodium valproate (contraindication to imipenem hydrate and cilastatin sodium)
- •8) Patients at risk of the following QT interval prolongation
- •(1) Patients with a history of torsade de pointe or other risk factors for heart failure
- •(2) Patients with hypokalemia requiring clinical consideration of treatment
- •(3) Patients with familial QT prolongation syndrome or a known family history of torsades de pointes
- •(4) Patients with an average QTcF greater than 450 msec measured 3 times at 5 plus or minus 1 minute intervals on a 12-lead ECG performed at screening
- •9) Patients receiving concomitant QT/QTc interval prolonging medications within 14 days prior to the start of treatment
- •10) Patients whose laboratory values at screening conflict with the following
- •(1) AST or ALT greater than or equal to 3 times the upper limit of the institutional reference value or total bilirubin greater than or equal to 2 times the upper limit of the institutional reference value
- •(2) eGFR (mL/min/1.73 m2) less than 30 mL/min
- •11) Patients with hearing loss or at risk of developing ototoxicity (deafness) due to concomitant medication (amikacin) [Patients should be referred to an otorhinolaryngologist if an abnormal hearing test (250-8000 Hz using air conduction) is detected during screening and an otorhinolaryngologist has confirmed that the patient has hearing loss or that the concomitant medication ( The patient should be excluded if an otolaryngologist determines that the patient has hearing loss or that ototoxicity (hearing loss) may occur with the use of concomitant medication (amikacin).
- •12) Patients with respiratory depression due to neuromuscular weakness, etc., who are judged by the investigator to have problems participating in the study.
- •13) Patients with a history of active primary, metastatic or other malignancy requiring treatment within 1 year prior to screening. (unless the malignancy is intraepithelial or has been cured by surgery or other treatment and the risk of recurrence is judged to be very low).
- •14) Patients with positive HIV antibody, HCV antibody, HBs antigen, HBs antibody, or HBc antibody at screening (however, even if the HBs antibody or HBc antibody test is positive, the patient may be included only if the HBV-DNA is measured and negative at the physician's discretion.)
- •15) Women with a p
研究者
相似试验
已完成
1 期
A Phase 1 Study of Olorofim in Healthy Japanese and Caucasian ParticipantsHealthy adult participantsJPRN-jRCT2031230016agata Tsutae24
已完成
1 期
A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers/AHealthy male volunteersOther -ACTRN12605000782639Epitan Limited6
招募中
不适用
A phase I study to evaluate the pharmacokinetic interactions and safety between Amlodipine/Valsartan combination tablet and Rosuvastatin in healthy adult volunteersDiseases of the circulatory systemKCT0001660Kyung Dong Pharmaceutical57
撤回
不适用
A Phase 1 Pharmacokinetic-Pharmacodynamic Study of Avelumab (MSB00100718C) in Patients with Previously Treated Advanced Stage Classical Hodgkin*s LymphomaHodgkin's Lymphomalymph node cancer10025319NL-OMON43446Pfizer15
进行中（未招募）
1 期
A Phase I study to investigate the pharmacokinetics and ECG effects of two single ascending doses of linaprazan glurate given as oral tablets to healthy subjectsErosive Gastroesophageal Reflux Disease (eGERD)MedDRA version: 20.1Level: LLTClassification code: 10017924Term: Gastroesophageal reflux Class: 10017947CTIS2024-516261-36-00Cinclus Pharma Holding AB (publ)63